- What is Accelmed's primary investment focus?
- Accelmed is a global group of funds investing in HealthTech companies, specifically medical devices, diagnostics, and digital health, across all stages.
- What was a recent notable exit for Accelmed?
- In May 2026, Accelmed saw an exit with EndoSpan being acquired by Artivion for $335M. Another notable exit was BioProtect, acquired by Almeda Ventures for $200M in January 2026.
- Which portfolio company did Accelmed exit in March 2025?
- Accelmed exited SoniVie in March 2025 when it was acquired by Boston Scientific for $400M.
- What is the most recent fund raised by Accelmed?
- Accelmed closed Fund 4 in March 2021, raising $400M.
- Can you name a recent acquisition of an Accelmed portfolio company in the cybersecurity sector?
- In July 2025, Cynerio, a cybersecurity for healthcare providers, was acquired by Axonius for $180M, representing an exit for Accelmed.
- What is Accelmed's investment strategy for its US-based fund?
- Accelmed Partners, its US-based fund, focuses on Buyout and Growth Investments in commercial HealthTech companies with over $10M LTM, targeting equity investments of $10-50M per transaction.
- What is the focus of Accelmed Ventures, its Israel-based fund?
- Accelmed Ventures, based in Israel, focuses on pre-commercialization and early revenue HealthTech opportunities, specifically in medical devices and digital health companies with innovative solutions for major chronic disease areas.
- Who are the co-founders of Accelmed?
- Accelmed was co-founded by Mori Arkin and Dr. Uri Geiger.